Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm A Smith

Showing results (21-30 of 188) with videos related to

Pageof 19
Sort By:
Cancer|May 24, 2014
Declining childhood and adolescent cancer mortalityMalcolm A Smith, Sean F Altekruse, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperativesBarry D Anderson, Peter C Adamson, Susan L Weiner, et al.
Journal of the National Cancer Institute|September 27, 2007
Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?Larry V Rubinstein, Janet E Dancey, Edward L Korn, et al.
Pediatric Blood & Cancer|December 13, 2006
SK-NEP-1 and Rh1 are Ewing family tumor linesMalcolm A Smith, Christopher L Morton, Doris Phelps, et al.
Oncology (Williston Park, N.Y.)|May 23, 2002
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2Malcolm A Smith, Janet E Dancey, Ewa Matczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Pediatric Blood & Cancer|May 22, 2008
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing programStephen T Keir, Christopher L Morton, Catherine Billups, et al.
Pediatric Blood & Cancer|October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testingMin H Kang, Malcolm A Smith, Christopher L Morton, et al.
Pediatric Blood & Cancer|December 23, 2011
Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing ProgramStephen T Keir, Christopher L Morton, Jianrong Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2013
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemiaHernan Carol, Barbara Szymanska, Kathryn Evans, et al.
Pageof 19

Showing results (21-30 of 188) with videos related to

Sort By:
Pageof 19
Cancer|May 24, 2014
Declining childhood and adolescent cancer mortalityMalcolm A Smith, Sean F Altekruse, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperativesBarry D Anderson, Peter C Adamson, Susan L Weiner, et al.
Journal of the National Cancer Institute|September 27, 2007
Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?Larry V Rubinstein, Janet E Dancey, Edward L Korn, et al.
Pediatric Blood & Cancer|December 13, 2006
SK-NEP-1 and Rh1 are Ewing family tumor linesMalcolm A Smith, Christopher L Morton, Doris Phelps, et al.
Oncology (Williston Park, N.Y.)|May 23, 2002
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2Malcolm A Smith, Janet E Dancey, Ewa Matczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Pediatric Blood & Cancer|May 22, 2008
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing programStephen T Keir, Christopher L Morton, Catherine Billups, et al.
Pediatric Blood & Cancer|October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testingMin H Kang, Malcolm A Smith, Christopher L Morton, et al.
Pediatric Blood & Cancer|December 23, 2011
Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing ProgramStephen T Keir, Christopher L Morton, Jianrong Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2013
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemiaHernan Carol, Barbara Szymanska, Kathryn Evans, et al.
Pageof 19